Biopharmaceutical companies are under increasing pressure to advance their molecules to first-in-human trials faster than ever before. For drug developers, this is a time-consuming, risky paradigm – on average, just one in every 1,000 of these molecules makes it out of Phase 1 trials. In this white paper we explore how we are able to guarantee customers five months from DNA to tox drug substance, and 11 months to Investigational New Drug designation (IND) filing for antibodies, using its Ibex® Design 2.0 Program.
Content Type: Whitepaper/Executive Summary
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center